Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06798207 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced

StatusRecruiting
PhasePhase 2
Started2025-03-13
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 18, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2025-07-16
Study Status, Study Design v4
Enrollment target90→170
2025-03-18
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v3
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-03→confirmed 2025-03-13
Study sites26→31
2025-02-13
Study Status, Contacts/Locations v2
Study sitescontacts updated at 1 of 26 sites
2025-02-09
Study Status, Contacts/Locations v1
Re-verified, no change to tracked fields
2025-01-23
Original filing
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. This is a Phase 2 study to evaluate the efficacy,and safety of TQB2102 for injection in recurrent/metastatic advanced gynecological tumors.
Trial Details
NCT Number NCT06798207
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Gynecological Tumors
Enrollment 170 participants
Start Date 2025-03-13
Primary Completion 2026-05 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2025-07-18